Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Consensus Rating of “Buy” from Brokerages

Avalyn Pharma Inc. (NASDAQ:AVLN) has received an average rating of “Buy” from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, two have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $59.00.

Several analysts have recently weighed in on the stock. Evercore assumed coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price target for the company. Morgan Stanley assumed coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They set an “overweight” rating and a $53.00 price target for the company. Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Guggenheim assumed coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $80.00 price target for the company. Finally, Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th.

Avalyn Pharma Stock Up 6.0%

Shares of NASDAQ:AVLN opened at $30.71 on Tuesday. Avalyn Pharma has a 1 year low of $24.15 and a 1 year high of $33.24. The company’s 50 day simple moving average is $28.77.

Avalyn Pharma (NASDAQ:AVLN) last posted its quarterly earnings results on Wednesday, June 3rd. The company reported ($21.83) earnings per share for the quarter, missing the consensus estimate of ($16.38) by ($5.45).

Insider Activity at Avalyn Pharma

In other Avalyn Pharma news, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of Avalyn Pharma stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the completion of the purchase, the insider directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This represents a 34.06% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jill Carroll acquired 277,778 shares of Avalyn Pharma stock in a transaction that occurred on Friday, May 1st. The stock was acquired at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the purchase, the director directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This represents a 14.55% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.